Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd cut its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) by 9.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 21,839 shares of the company’s stock after selling 2,367 shares during the period. Y Intercept Hong Kong Ltd owned 0.08% of Castle Biosciences worth $582,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. R Squared Ltd acquired a new position in Castle Biosciences in the 4th quarter valued at $42,000. Quest Partners LLC raised its holdings in Castle Biosciences by 54.4% in the 3rd quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock valued at $123,000 after acquiring an additional 1,522 shares during the last quarter. US Bancorp DE raised its holdings in Castle Biosciences by 1,889.2% in the 3rd quarter. US Bancorp DE now owns 4,615 shares of the company’s stock valued at $132,000 after acquiring an additional 4,383 shares during the last quarter. Point72 DIFC Ltd acquired a new position in Castle Biosciences in the 3rd quarter valued at $140,000. Finally, Assetmark Inc. raised its holdings in Castle Biosciences by 16.8% in the 3rd quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock valued at $149,000 after acquiring an additional 748 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Castle Biosciences news, insider Derek J. Maetzold sold 9,364 shares of the business’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $28.34, for a total value of $265,375.76. Following the transaction, the insider now owns 84,762 shares in the company, valued at $2,402,155.08. The trade was a 9.95 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Daniel Bradbury sold 7,867 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $29.14, for a total transaction of $229,244.38. Following the completion of the transaction, the director now owns 1,425 shares in the company, valued at $41,524.50. This represents a 84.66 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 30,771 shares of company stock valued at $886,112. Company insiders own 7.20% of the company’s stock.

Castle Biosciences Stock Down 14.2 %

Shares of Castle Biosciences stock opened at $21.68 on Friday. The company has a fifty day moving average price of $27.23 and a 200 day moving average price of $29.17. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a twelve month low of $16.97 and a twelve month high of $35.84. The stock has a market cap of $607.19 million, a price-to-earnings ratio of 108.41 and a beta of 0.91.

Analysts Set New Price Targets

Several brokerages have weighed in on CSTL. KeyCorp boosted their price target on Castle Biosciences from $28.00 to $36.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Scotiabank boosted their price objective on shares of Castle Biosciences from $37.00 to $44.00 and gave the company a “sector outperform” rating in a research note on Wednesday, November 6th. Robert W. Baird boosted their price objective on shares of Castle Biosciences from $36.00 to $37.00 and gave the company an “outperform” rating in a research note on Friday. Stephens reissued an “overweight” rating and set a $41.00 price objective on shares of Castle Biosciences in a research note on Thursday, January 2nd. Finally, Lake Street Capital boosted their price objective on shares of Castle Biosciences from $34.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Castle Biosciences currently has an average rating of “Buy” and a consensus price target of $40.00.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.